Xencor Inc [XNCR] stock prices are up 4.29% to $23.83 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The XNCR shares have gain 4.56% over the last week, with a monthly amount glided 26.82%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 28, February 2024, Xencor to Present at Upcoming Investor Conferences. In a post published today on Yahoo Finance, Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that company management will participate at multiple upcoming investor conferences:.
From an analyst’s perspective:
Xencor Inc [NASDAQ: XNCR] stock has seen the most recent analyst activity on February 28, 2024, when Piper Sandler downgraded its rating to a Neutral and also revised its price target to $24 from $37. Previously, BofA Securities started tracking the stock with Buy rating on May 19, 2023, and set its price target to $42. On December 06, 2022, Cowen initiated with a Outperform rating. Raymond James upgraded its rating to a Strong Buy but stick to its price target of $58 on October 13, 2022. JP Morgan initiated its recommendation with a Overweight and recommended $37 as its price target on September 21, 2022. In a note dated February 11, 2022, BMO Capital Markets initiated an Outperform rating and provided a target price of $54 on this stock.
The stock price of Xencor Inc [XNCR] has been fluctuating between $16.49 and $32.00 over the past year. Currently, Wall Street analysts expect the stock to reach $56 within the next 12 months. Xencor Inc [NASDAQ: XNCR] shares were valued at $23.83 at the most recent close of the market. An investor can expect a potential return of 135.0% based on the average XNCR price forecast.
Analyzing the XNCR fundamentals
The Xencor Inc [NASDAQ:XNCR] reported sales of 168.34M for trailing twelve months, representing a surge of 106.80%. Gross Profit Margin for this corporation currently stands at 0.95% with Operating Profit Margin at -0.82%, Pretax Profit Margin comes in at -0.72%, and Net Profit Margin reading is -0.74%. To continue investigating profitability, this company’s Return on Assets is posted at -0.13, Equity is -0.19 and Total Capital is -0.16.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 23.22 points at the first support level, and at 22.60 for the second support level. However, for the 1st resistance point, the stock is sitting at 24.26, and for the 2nd resistance point, it is at 24.68.
Xencor Inc [XNCR] reported earnings per share of -$0.31 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.09/share, meaning a difference of -$0.22 and a surprise factor of -244.40%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.4 per share as compared to estimates of -$0.73 per share, a difference of $0.33 representing a surprise of 45.20%.
Ratios To Look Out For
It’s worth pointing out that Xencor Inc [NASDAQ:XNCR]’s Current Ratio is 7.36. Further, the Quick Ratio stands at 7.36. Considering the valuation of this stock, the price to sales ratio is 8.65, the price to book ratio is 2.17.
Transactions by insiders
Recent insider trading involved GORMAN KEVIN CHARLES, Director, that happened on Feb 13 ’24 when 53.0 shares were purchased. SR. VICE PRESIDENT & CSO, Desjarlais John R completed a deal on Feb 13 ’24 to sell 54108.0 shares. Meanwhile, PRESIDENT & CEO Dahiyat Bassil I sold 45000.0 shares on Dec 29 ’23.
